AVP-786

deudextromethorphan hydrobromide/quinidine sulfate · Otsuka Pharmaceutical Development & Commercialization, Inc.

Drug timelines are a Plus or Pro feature.

16 regulatory and trial events tracked for AVP-786, covering 2014-06-26 to 2025-10-29. Get the full timeline:

Most recent: Clinical Trial Update: Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury [Phase 2]

See pricing